Brief: Bone Therapeutics' Allob Phase IIA Study Results Positive

Biosenic SA

14/10/2020 07:14

Oct 14 (Reuters) - Bone Therapeutics SA  BOTHE.BR :
    * REG-BONE THERAPEUTICS’ ALLOGENEIC CELL THERAPY PRODUCT,
ALLOB,
SHOWS 90% FUSION RATE AT 24 MONTHS IN PHASE IIA STUDY IN LUMBAR
SPINAL FUSION
    * POSITIVE 24-MONTH FOLLOW-UP RESULTS FOR PHASE IIA STUDY
WITH
ALLOGENEIC CELL THERAPY PRODUCT, ALLOB, IN PATIENTS UNDERGOING
LUMBAR SPINAL FUSION PROCEDURES

Source text for Eikon:  ID:nGNE7TNxsM 
Further company coverage:  BOTHE.BR 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 778 51 10;))